GW Pharma: Focused on epilepsy

5:22 PM ET Tue, 14 Oct 2014

GW Pharma shares are down sharply after a study of its treatment for ulcerative colitis missed its primary endpoint in a mid-stage trial. GW Pharmaceuticals CEO Justin Gover, says the company's main focus is on its product for epilepsy.